Zacks Investment Research Upgrades Advanz Pharma (CXRXF) to Hold
According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “
CXRXF has been the subject of several other research reports. ValuEngine raised Advanz Pharma from a sell rating to a hold rating in a research note on Friday, March 1st. Bloom Burton reissued a hold rating on shares of Advanz Pharma in a research note on Friday, March 15th.
Advanz Pharma (OTCMKTS:CXRXF) last released its quarterly earnings results on Thursday, March 14th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $117.57 million during the quarter. On average, analysts forecast that Advanz Pharma will post -2.96 EPS for the current year.
About Advanz Pharma
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
Further Reading: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.